📊 PCRX Key Takeaways
Is Pacira BioSciences, Inc. (PCRX) a Good Investment?
Pacira demonstrates improving profitability with 107% net income growth and strong free cash flow generation ($136.7M), supported by solid balance sheet fundamentals and excellent liquidity. However, the company faces headwinds from very thin profit margins (1.0% net), modest revenue growth (3.6% YoY), and critically weak interest coverage (1.1x) that leaves minimal buffer for debt service obligations.
Why Buy Pacira BioSciences, Inc. Stock? PCRX Key Strengths
- Strong free cash flow generation of $136.7M with 18.8% FCF margin despite low net margins
- Excellent liquidity position with 4.54x current ratio and reasonable leverage at 0.54x debt-to-equity
- Significant profitability improvement with net income and EPS nearly doubling year-over-year
PCRX Stock Risks: Pacira BioSciences, Inc. Investment Risks
- Critically weak interest coverage ratio of 1.1x provides minimal buffer for debt service; vulnerable to revenue decline
- Very thin net profit margins (1.0%) and operating margins (2.6%) limit earnings power and reinvestment capacity
- Modest revenue growth rate (3.6% YoY) combined with extremely low returns on equity (1.0%) and assets (0.6%)
Key Metrics to Watch
- Interest coverage ratio trend and debt service sustainability
- Operating and net margin expansion relative to revenue growth
- Quarterly revenue growth rate and operating cash flow consistency
Pacira BioSciences, Inc. (PCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.54x current ratio provides a solid financial cushion.
PCRX Profit Margin, ROE & Profitability Analysis
PCRX vs Healthcare Sector: How Pacira BioSciences, Inc. Compares
How Pacira BioSciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pacira BioSciences, Inc. Stock Overvalued? PCRX Valuation Analysis 2026
Based on fundamental analysis, Pacira BioSciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pacira BioSciences, Inc. Balance Sheet: PCRX Debt, Cash & Liquidity
PCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pacira BioSciences, Inc.'s revenue has grown significantly by 70% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.89 reflects profitable operations.
PCRX Revenue Growth, EPS Growth & YoY Performance
PCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $168.6M | $5.4M | $0.12 |
| Q2 2025 | $178.0M | -$35.0K | $0.00 |
| Q1 2025 | $167.1M | $4.8M | $0.10 |
| Q3 2024 | $163.9M | $10.9M | $0.23 |
| Q2 2024 | $169.5M | $6.2M | $0.13 |
| Q1 2024 | $160.3M | $9.0M | $0.19 |
| Q3 2023 | $163.9M | -$693.0K | $-0.02 |
| Q2 2023 | $169.4M | $6.2M | $0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pacira BioSciences, Inc. Dividends, Buybacks & Capital Allocation
PCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pacira BioSciences, Inc. (CIK: 0001396814)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCRX
What is the AI rating for PCRX?
Pacira BioSciences, Inc. (PCRX) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCRX's key strengths?
Claude: Strong free cash flow generation of $136.7M with 18.8% FCF margin despite low net margins. Excellent liquidity position with 4.54x current ratio and reasonable leverage at 0.54x debt-to-equity.
What are the risks of investing in PCRX?
Claude: Critically weak interest coverage ratio of 1.1x provides minimal buffer for debt service; vulnerable to revenue decline. Very thin net profit margins (1.0%) and operating margins (2.6%) limit earnings power and reinvestment capacity.
What is PCRX's revenue and growth?
Pacira BioSciences, Inc. reported revenue of $726.4M.
Does PCRX pay dividends?
Pacira BioSciences, Inc. does not currently pay dividends.
Where can I find PCRX SEC filings?
Official SEC filings for Pacira BioSciences, Inc. (CIK: 0001396814) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCRX's EPS?
Pacira BioSciences, Inc. has a diluted EPS of $0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PCRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pacira BioSciences, Inc. has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PCRX stock overvalued or undervalued?
Valuation metrics for PCRX: ROE of 1.0% (sector avg: 15%), net margin of 1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PCRX stock in 2026?
Our dual AI analysis gives Pacira BioSciences, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCRX's free cash flow?
Pacira BioSciences, Inc.'s operating cash flow is $152.0M, with capital expenditures of $15.3M. FCF margin is 18.8%.
How does PCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.0% (avg: 12%), ROE 1.0% (avg: 15%), current ratio 4.54 (avg: 2).